Ayla Ellison

Fierce Pharma Week brought thousands of people to Philadelphia for four days of conversations about pharma marketing, commercialization, medical affairs and communications.

For years, health systems have been working to address their environmental impact. These efforts are largely voluntary and require systemwide buy-in to be effective.

With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. Now, the CEO of a buzzy pattern hair loss biotech is eyeing opportunities in an evolving market that could expand well beyond his own company.

A growing number of clinicians are looking to work in healthcare as independent contractors, giving them more flexibility over when and how they work.

What does it mean to be a Fierce 15 biotech in 2026? With this year's list unveiled, the Fierce Biotech team gets together to discuss what the winners tell us about the state of the sector.

Serious mental illness (SMI) is challenging to address. Individuals with SMI die significantly earlier and are nearly twice as likely to have

In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new opportunities in the pharmaceutical industry.

Breakdowns in patient navigation can have consequences beyond patient frustration, contributing to missed appointments, avoidable emergency department visits and lost revenue for healthcare organizations.

In this week's episode of "The Top Line," we're covering a pair of FDA approvals for GSK, an antibody-drug conjugate pact worth up to $15 billion and the growing role of point-of-care advertising in pharmaceutical marketing.

Pediatric developmental care is notoriously difficult to navigate. Providers often find it challenging to accept insurance, and provider shortages mean long waitlists for families at a time when every day without care counts.